3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorobenzonitrile | 1527474-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorobenzonitrile
• 英文别名: 3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorobenznitrile
• CAS: 1527474-04-9
• 化学式: C₁₅H₁₂FN₅
• 分子量: 281.292
• InChiKey: JQMHPASIGUDQDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20140005183A1

  公开（公告）日：2014-01-02

  The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了一种新型的4,5-二取代-7H-吡咯并[2,3-d]嘧啶衍生物I式，以及其药学上可接受的盐，其中R1、R2、R3、R4和R5如规范所定义。本发明还涉及含有I式化合物的制药组合物，以及用于治疗与LRRK2相关的疾病，如神经退行性疾病，包括帕金森病或阿尔茨海默病，癌症，克隆病或麻风病的化合物的用途。
• Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20150366874A1

  公开（公告）日：2015-12-24

  The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新型的4,5-二取代-7H-吡咯并[2,3-d]嘧啶衍生物I式及其药物可接受的盐，其中R1、R2、R3、R4和R5如规范中所定义。本发明还涉及包括I式化合物的制药组合物以及在治疗与LRRK2相关的疾病，如神经退行性疾病（包括帕金森病或阿尔茨海默病）、癌症、克罗恩病或麻风病中使用该化合物的用途。
• NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2867236B1

  公开（公告）日：2017-06-14
• PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF
  申请人：Denali Therapeutics Inc.

  公开号：US20210147573A1

  公开（公告）日：2021-05-20

  In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY. Methods and materials for detecting LRRK2 and Rab protein are also provided.
• US9156845B2
  申请人：——

  公开号：US9156845B2

  公开（公告）日：2015-10-13